CXCR4 and renal cell carcinoma: Thus, CXCR4 expression could be a potential biomarker of prognosis and a drug target for personalized treatments for patients with RCC [113], but the evidence is still lacking and more studies are needed to determine whether 68Ga-Pentixafor can reliably detect CXCR4 expression in vivo in patients with RCC.